Deal of the Week: Boston Scientific/Apama

Boston Scientific Corporation (NYSE: BSX) announced its second acquisition of the year, targeting privately held Apama Medical Inc. in a deal for $175 million. That’s small potatoes compared with its previously announced deal for Symetis SA, the Swiss maker of transcatheter aortic valve implantation devices, for $435 million.

Medical Device Deals Stay Strong in 2016

Medical Devices is finishing the year on a high note. In fact, as of December 29, 2016, deal volume reached 113 transactions, equal to 2015’s total. Deal value topped off at $61.3 billion, a 111% increase from last year’s total of $29.1 billion.

Boston Scientific Seeks Out Portfolio Acquisitions

Earlier this year, Boston Scientific Corporation (NYSE: BSX) acquired two companies: Cosman Medical Inc. to strengthen its neuromodulation business and EndoChoice Holdings Inc. to strengthen its pathology services and imaging technologies. Since then, the medical device giant has toned down its acquiring habits with two asset/portfolio purchases in November. On November 3, 2016, the company acquired the […]

Medical Device Sector Picks Up in Q3:16

In the first eight months of 2016, 80 transactions were announced in the Medical Device sector, making it unlikely this year’s deal volume would surpass last year’s total of 114 deals. As the third quarter wraps up, the sector’s deal volume has reached 90 deals: 31 in Q1, 27 in Q2, and 32 as of […]

Boston Scientific Buys Interventional Radiology Business

The medical device sector just keeps plugging along with its mergers and acquisitions, with four announcements already in November. One was Boston Scientific Corporation (NYSE: BSX), which announced its acquisition of the interventional radiology business of CeloNova Biosciences, a global developer and manufacturer of endovascular and interventional cardiology technologies. The price was $70 million upfront, plus […]

March Healthcare M&A Madness

March isn’t quite over as we write this, and neither is the madness—which won’t stop us from posting the biggest deals of the month. As of Friday, March 27, $34.4 billion has been committed to finance about 105 transactions. Of course, $21 billion of that comes from the AbbVie (NYSE: ABBV) acquisition of Pharmacyclics (NASDAQ: […]

Year’s Biggest Billion-Dollar Deals Top $64 Billion

Already in 2015, we’ve recorded 11 billion-dollar-plus deals, for a total of $64.4 billion. Thanks to the $21 billion AbbVie (NYSE: ABBV) bid for Pharmacyclics (NASDAQ: PCYC), the biotechnology sector accounted for $27.5 billion of those big deals. Pharmaceuticals, with four billion-plus transactions, still ranks first, with combined spending of $30.45 billion.